GSK’s Nucala for severe eosinophilic asthma gains approval in China
GSK has gained approval from the China National Medical Products Administration for Nucala (mepolizumab) for severe eosinophilic asthma.
GSK has gained approval from the China National Medical Products Administration for Nucala (mepolizumab) for severe eosinophilic asthma.
What's Your Reaction?
